Neurocrine Biosciences | NBIX - 負債





負債 変化する 日付
AbbVie USD 67.5B 67.5B 2025-12
Acadia Pharmaceuticals USD 52.19M 2.62M 2025-12
Agios Pharmaceuticals USD 40.21M 4.31M 2025-12
ALKERMES USD 1.58B 1.51B 2026-03
Alnylam Pharmaceuticals USD 1.28B 30.06M 2025-12
Amgen USD 54.6B 17M 2025-12
Biogen USD 6.56B 275.1M 2026-03
BioMarin Pharmaceutical USD 1.44B 833.74M 2026-03
Cytokinetics USD 1.29B 4.48M 2026-03
Enanta Pharmaceuticals USD 1.35M 0 2024-12
Exelixis USD 169.54M 3.5M 2026-03
Gilead Sciences USD 24.94B 5M 2025-12
Halozyme Therapeutics USD 2.14B 2.01M 2026-03
Incyte USD 39.43M 982K 2026-03
Ionis Pharmaceuticals USD 2.34B 9.5M 2026-03
Nektar Therapeutics USD 0 0 2022-06
Neurocrine Biosciences USD 406.2M 9.1M 2026-03
Pfizer USD 63.73B 231M 2026-03
Prothena USD 9.08M 699K 2025-09
Regeneron Pharmaceuticals USD 2.71B 300K 2026-03
Repligen USD 546.58M 4.37M 2026-03
Rigel Pharmaceuticals USD 59.69M 90K 2024-06
Sarepta Therapeutics USD 1.04B 210.44M 2025-12
Teva Pharmaceutical Industries USD 17.09B 21M 2025-12
Ultragenyx Pharmaceutical USD 36M 2.17M 2025-12
Vertex Pharmaceuticals USD 1.99B 44M 2026-03
Xoma USD 120.79M 3.27M 2024-06